<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83933">
  <stage>Registered</stage>
  <submitdate>18/05/2009</submitdate>
  <approvaldate>2/06/2009</approvaldate>
  <actrnumber>ACTRN12609000406202</actrnumber>
  <trial_identification>
    <studytitle>Improving pain relief following Total Knee Replacement</studytitle>
    <scientifictitle>The effect of Continuous Femoral Nerve Infusion versus Conventional Analgesia on pain levels following Total Knee Arthroplasty: A prospective randomised, double blind, placebo controlled Trial</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Analgesia following total knee replacement</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>the treatment arm of the study will have a femoral nerve infusion of Bupivicaine 0.125% running at 10ml/hr for 48 hours after total knee replacement while the placebo will have saline running for 48 hours.
all patients will have an intraoperative femoral nerve injection of 15ml Bupivicaine 0.25% along with subarachnoid blockade using 10-20mcg 0.5% bupivicaine + 3mcg/kg Morphine.
Sedation using Midazolam/Propofol titrated to effect or General Anaesthetic (GA)</interventions>
    <comparator>saline running into femoral nerve catheter rather than local anaesthetic for 48 hours</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: surgery</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>pain at rest (visual analogue scale)</outcome>
      <timepoint>from day 1 post operation for next 72 hours, , measured every 8 hours</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>nerve infusion rate using information from infusion pump and bedside chart</outcome>
      <timepoint>up to 72 hours following operation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>cumulative dose of narcotics calculated using infusion pump information</outcome>
      <timepoint>up to 72 hours following operation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>18-85 years
Body Mass Index (BMI) less than 40
undergoing primary total knee replacement
ability to give informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>BMI greater than 40
older than 85
contraindication to femoral nerve catheter
major medical comorbidity</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>enrolling at preoperative assessment
allocated to treatment or non treatment arm postoperatively in recovery
allocation concealed by sealed opaque envelope</concealment>
    <sequence>computer software</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>27/05/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>jean-claude theis</primarysponsorname>
    <primarysponsoraddress>department of orthopaedics
dunedin hospital
201 great king st
dunedin 9016</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>richard stewart scholarship
university of otago</fundingname>
      <fundingaddress>Dunedin basic medical sciences course trust
otago medical school
po box 913
dunedin 9054</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>jason locker</sponsorname>
      <sponsoraddress>340 portobello road
challis point
dunedin 
RD2 9077</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Studies have shown that femoral nerve infusions post total knee replacement may improve pain relief but a double blind, placebo controlled trial has not been conducted.
Null hypothesis is that a continuous infusion of local anaesthetic for 48 hours post operation makes no difference to pain levels</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>lower south regional ethics committee</ethicname>
      <ethicaddress>ministry of health
229 moray place
po box 5849
dunedin
no postcode but courier address:
c/o ministry of health
229 moray place
dunedin</ethicaddress>
      <ethicapprovaldate>12/02/2009</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>jason locker</name>
      <address>department  of orthopaedics
dunedin hospital
201 great king street
dunedin 9013</address>
      <phone>+64 3 474 0999 pager 6944</phone>
      <fax />
      <email>jason.locker@otagodhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>jason locker</name>
      <address>department of orthopaedics
dunedin hospital
201 great king street
dunedin 9013</address>
      <phone>+64 3 474 0999 pager 6944</phone>
      <fax />
      <email>jason.locker@otagodhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>